A Randomized, Phase 3 Study of Dose Escalation Versus No Dose Escalation of Imatinib In Metastatic GIST Patients With Imatinib Trough Levels Less Than 1100 Nanograms/mL.
Phase of Trial: Phase III
Latest Information Update: 15 Aug 2013
At a glance
- Drugs Imatinib (Primary)
- Indications Gastrointestinal stromal tumours
- Focus Therapeutic Use
- 20 Jul 2011 Planned End Date changed from 1 Dec 2014 to 1 Jun 2011 as reported by ClinicalTrials.gov.
- 26 May 2011 Status changed from active, no longer recruiting to discontinued as reported by ClinicalTrials.gov.
- 08 Mar 2011 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.